Fresh Recalls

FDAClass II · Drug · Recall D-0653-2026 · Recalled July 8, 2026

IMULDOSA recall — ACCORD BIOPHARMA INC

Agency report date: July 8, 2026.

1. Compare your item

This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.

Product named
IMULDOSA
Company / brand
ACCORD BIOPHARMA
Lot / serial / date codes
Lot # 004L24A, Exp Date: 02/19/2027.
Distribution
US Nationwide.
Agency product description and boundaries

IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose vial, Manufactured by Accord BioPharma Inc., 8041 Arco corporate Drive, Suite 200, Raleigh, NC 27617, USA, Manufactured at: Catalent Indiana, LLC, 1300 S. Patterson Drive, Bloomington, IN 47403, USA, NDC 69448-019-26.

Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.

If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.

2. Agency hazard and consumer action

FDA reports: Lack of assurance of Sterility:

No consumer remedy instructions are supplied in this record. Check the official notice and listed company contact for the agency’s current instructions.

Class II: may cause temporary or medically reversible health consequences.

Affected product: IMULDOSA

3. Open the official notice or contact

Official recall ID
D-0653-2026
Brand
ACCORD BIOPHARMA
Classification
Class II
Units affected
326 vials
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Affected products

Companies & origin

Recalling firm location
Raleigh, NC, United States
Firm address
8041 Arco Corporate Dr Ste 200, N/A, 27617-2091

Identifying details (verbatim from the notice)

Product codes / lots
Lot # 004L24A, Exp Date: 02/19/2027.
Distribution
US Nationwide.
Firm notified the public via
Letter
FDA event ID
99216
Recall initiated
June 10, 2026
FDA classified
June 29, 2026
FDA report date
July 8, 2026
Verify with the official sources:

Found something wrong or missing? Report a data error.

Source: U.S. Food & Drug Administration. Agency excerpts come from the public data feed and may omit tables or later changes; the linked government source is authoritative. Source last checked September 7, 2026 at 6:00 AM UTC. Record retrieved September 7, 2026 at 6:00 AM UTC.

Report a data error on this page